Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO131921 in Relapsed/Refractory Indolent NHL
NCT00452127Phase 2Terminated
- Sponsor
- Genentech
- Start
- May 2007
- Primary completion
- May 2009
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of PRO131921 in Indolent Non-Hodgkin Lymphoma (INHL), sponsored by Genentech. Primary endpoint: Dose-limiting toxicities and adverse events. Started May 2007; status: terminated.
02
Drugs
PRO131921
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT00452127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00452127.